Antifungal Drug Discovery: Something Old and Something New

1. LaiCC, TanCK, HuangYT, ShaoPL, HsuehPR (2008) Current challenges in the management of invasive fungal infections. J Infect Chemother 14: 77–85.

2. ParkBJ, WannemuehlerKA, MarstonBJ, GovenderN, PappasPG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525–530.

3. BrownGD, DenningsDW, LevitzSM (2012) Tackling human fungal infections. Science 336: 647.

4. BlankenshipJR, SteinbachWJ, PerfectJR, HeitmanJ (2003) Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investig Drugs 4: 192–199.

5. CowenLE, SinghSD, KohlerJR, CollinsC, ZaasAK, et al. (2009) Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 106: 2818–2823.

6. ZhaiB, WuC, WangL, SachsMS, LinX (2012) The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother 56: 3758–3766.

7. BregerJ, FuchsBB, AperisG, MoyTI, AusubelFM, et al. (2007) Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 3: e18 doi:10.1371/journal.ppat.0030018.

8. SpitzerM, GriffithsE, BlakelyKM, WildenhainJ, EjimL, et al. (2011) Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol 7: 499.

9. RoemerT, XuD, SinghSB, ParishCA, HarrisG, et al. (2011) Confronting the challenges of natural product-based antifungal discovery. Chem Biol 18: 148–164.

10. TebbetsB, StewartD, LawryS, NettJ, NantelA, et al. (2012) Identification and characterization of antifungal compounds using a saccharomyces cerevisiae reporter bioassay. PLoS ONE 7: e36021 doi:10.1371/journal.pone.0036021.

11. KrysanDJ, DidoneL (2008) A high-throughput screening assay for small molecules that disrupt yeast cell integrity. J Biomol Screen 13: 657–664.

12. WisemanH, CannonM, ArnsteinHR (1989) Observation and significance of growth inhibition of Saccharomyces cerevisiae (A224A) by the anti-oestrogen drug tamoxifen. Biochem Soc Trans 17: 1038–1039.

13. DolanK, MontgomeryS, BuchheitB, DidoneL, WellingtonM, et al. (2009) Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob Agents Chemother 53: 3337–3346.

14. WalkerSS, XuY, TriantafyllouI, WaldmanMF, MendrickC, et al. (2011) Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors. Antimicrob Agents Chemother 55: 5099–5106.

15. KitamuraA, SomeyaK, HataM, NakajimaR, TakemuraM (2009) Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis. Antimicrob Agents Chemother 53: 670–677.

16. MiyazakiM, HoriiT, HataK, WatanabeNA, NakamotoK, et al. (2011) In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob Agents Chemother 55: 4652–4658.

17. HataK, HoriiT, MiyazakiM, WatanabeNA, OkuboM, et al. (2011) Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. Antimicrob Agents Chemother 55: 4543–4551.

18. McLellanCA, WhitesellL, KingOD, LancasterAK, MazitschekR, et al. (2012) Inhibiting GPI anchor biosynthesis in fungi stress the endoplasmic reticulum and enhances immunogencity. ACS Chem Biol. E-pub ahead of print doi.org/10.1021/cb300235m.

19. BaxterBK, DiDoneL, OguD, SchorS, KrysanDJ (2011) Identification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules. ACS Chem Biol 6: 502–510.